Sort   by:  
 Page size 
GenomicsExpression data from graft infiltrating macrophages treated with mTORi-HDL nanobiologics
Expression data from graft infiltrating macrophages treated with mTORi-HDL nanobiologics
PRJNA488999 | ENA
TranscriptomicsExpression data from graft infiltrating macrophages treated with mTORi-HDL nanobiologics
Inducing graft acceptance without chronic immunosuppression remains an elusive goal in organ transplantation. Recent data demonstrate that non-self recognition by graft infiltrating macrophages initiates transplant rejection. Using an experimental transplantation mouse model, we isolated graft-infil...
ORGANISM(S): Mus musculus 
2018-10-31 | GSE119370 | GEO
UnknownClinical Benefit of Niraparib to TKI/mTORi-Resistance Metastatic ccRCC With BAP1-Frame Shift Mutation: Case Report and Literature Review.
Not available
S-EPMC9299075 | biostudies-literature
ProteomicsMYC is a clinically significant determinant of mTOR inhibitor resistance in breast cancer
Targeting the PI3K-AKT-mTOR pathway is a promising therapeutic strategy for breast cancer treatment. However, low response rates and the development of acquired resistance to PI3K-AKT-mTOR inhibitors remain major challenges for successful patient treatment. Here, we show that MYC activation is a cen...
ORGANISM(S): Mus musculus (Mouse) 
2023-05-02 | PXD041927 | Pride
Azd8055 Pi3k-akt-mtor signaling pathway Myc Tumor Mtori Lc-msms Mouse invasive lobular carcinoma Ilc 
GenomicsSingle-cell multiome uncovers differences in glycogen metabolism underlying species-specific speed of development [mTORi]
Single-cell multiome uncovers differences in glycogen metabolism underlying species-specific speed of development [mTORi]
PRJNA1151688 | ENA
GenomicsCombination treatment of mTORi with BETi inhibits the Myc network in PDAC
Targeting MYC sensitizes pancreatic cancer cells to MTOR inhibition
PRJEB47050 | ENA
TranscriptomicsMyeloid-avid mTOR-inhibiting nanobiologic attenuates allograft fibrosis after lung transplantation
Chronic lung allograft dysfunction (CLAD) is characterized by fibrotic graft remodeling and limits long-term survival after pulmonary transplantation. Despite clinical evidence that myeloid cells drive conditions that increase the risk of CLAD development, contemporary immunosuppression primarily ta...
ORGANISM(S): Mus musculus 
2026-06-29 | GSE314602 | GEO
GenomicsNucleolin aptamer N6L reprograms the translational machinery and acts synergistically with mTORi to inhibit pancreatic cancer proliferation
Nucleolin aptamer N6L reprograms the translational machinery and acts synergistically with mTORi to inhibit pancreatic cancer proliferation
PRJNA766664 | ENA
TranscriptomicsGlioma-associated microglia and macrophages as a potential target for mTOR inhibition in glioblastoma
Introduction: Glioma-associated microglia/macrophages (GAM) constitute the predominant immune cell population in glioblastoma (GB). Both GB cells and GAM exhibit upregulated mTOR signaling. This study aimed to investigate the effects of pharmacological mTOR inhibition (mTORi) specifically on GAM.Mat...
ORGANISM(S): Homo sapiens 
2025-07-28 | GSE242829 | GEO
TranscriptomicsPMEPA1 mediates resistance to mTOR inhibitors in triple-negative breast cancer via dual modulation of TGF-β signaling and PI3K/AKT activation
Acquired resistance to mammalian target of rapamycin inhibitors (mTORi) severely limits their clinical efficacy in triple-negative breast cancer (TNBC), a subtype devoid of targeted therapeutic options. To model acquired resistance, we established two mTORi-resistant TNBC cell lines, MDA-MB-231/DREV...
ORGANISM(S): Homo sapiens 
2026-03-06 | GSE309057 | GEO
Sort   by:  
 Page size